NasdaqCM:OCGNBiotechs
Ocugen (OCGN): Valuation Pressures Challenge Bullish Narrative as Profitability Remains Elusive
Ocugen (OCGN) is projected to deliver rapid revenue growth of 75.3% per year, with earnings expected to rise 77.45% annually, both far exceeding the broader US market estimates. The company remains unprofitable, having posted a 3.8% average annual increase in losses over the past five years, and its share price currently trades at $1.38. Investors will weigh these aggressive growth forecasts against Ocugen’s continued net margin struggles and premium valuation, especially given a...